173 related articles for article (PubMed ID: 18954439)
41. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
42. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury.
Yang K; Palm J; König J; Seeland U; Rosenkranz S; Feiden W; Rübe C; Rübe CE
Int J Radiat Biol; 2007 Oct; 83(10):665-76. PubMed ID: 17729161
[TBL] [Abstract][Full Text] [Related]
43. Relationship between matrix metalloproteinases MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinases-1 and IL-5, IL-8 in nasal polyps.
Chen YS; Langhammer T; Westhofen M; Lorenzen J
Allergy; 2007 Jan; 62(1):66-72. PubMed ID: 17156344
[TBL] [Abstract][Full Text] [Related]
44. MMPs, TIMP-2, and TGF-beta1 in the cancerization of oral lichen planus.
Chen Y; Zhang W; Geng N; Tian K; Jack Windsor L
Head Neck; 2008 Sep; 30(9):1237-45. PubMed ID: 18642282
[TBL] [Abstract][Full Text] [Related]
45. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
[TBL] [Abstract][Full Text] [Related]
46. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
47. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
Matsunaga Y; Koda M; Murawaki Y
Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
[TBL] [Abstract][Full Text] [Related]
48. Metalloproteinases in juvenile angiofibroma--a collagen rich tumor.
Duerr S; Wendler O; Aigner T; Karosi S; Schick B
Hum Pathol; 2008 Feb; 39(2):259-68. PubMed ID: 17950779
[TBL] [Abstract][Full Text] [Related]
49. The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide.
Hemmerlein B; Johanns U; Halbfass J; Böttcher T; Heuser M; Radzun HJ; Thelen P
Int J Oncol; 2004 May; 24(5):1069-76. PubMed ID: 15067327
[TBL] [Abstract][Full Text] [Related]
50. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
[TBL] [Abstract][Full Text] [Related]
52. [The expression of matrix metalloproteinases and their tissue inhibitors in pleomorphic adenoma].
Chen Y; Tian K; Geng N; Yang MZ; Zhang WP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Jan; 40(1):58-61. PubMed ID: 15774155
[TBL] [Abstract][Full Text] [Related]
53. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS
Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538
[TBL] [Abstract][Full Text] [Related]
54. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
Voland P; Besig S; Rad R; Braun T; Baur DM; Perren A; Langer R; Höfler H; Prinz C
Neuroendocrinology; 2009; 89(1):66-78. PubMed ID: 18708724
[TBL] [Abstract][Full Text] [Related]
55. Significant relation of tissue inhibitor of matrix metalloproteinase-2 and its combination with matrix metalloproteinase-2 to survival of patients with cancer of uterine cervix.
Wang PH; Ko JL; Yang SF; Tsai HT; Tee YT; Han CP; Lin LY; Chen SC; Shih YT
Reprod Sci; 2011 Aug; 18(8):798-808. PubMed ID: 21422052
[TBL] [Abstract][Full Text] [Related]
56. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT
J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946
[TBL] [Abstract][Full Text] [Related]
57. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
58. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
59. [Expression of matrix metalloproteinases and their inhibitors in the internal carotid artery wall in pathological tortuosity].
Paltseva EM; Polyakova VO; Oskolkova SA; Abramyan AV; Ivanova AG; Krylova YS; Gavrilenko AV
Arkh Patol; 2016; 78(3):26-31. PubMed ID: 27296003
[TBL] [Abstract][Full Text] [Related]
60. Expression of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 1 in nonrecurrent vs recurrent nasal polyps.
Yeo NK; Eom DW; Oh MY; Lim HW; Song YJ
Ann Allergy Asthma Immunol; 2013 Sep; 111(3):205-10. PubMed ID: 23987197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
